UNLABELLED: OBJECTIVE/ INTRODUCTION: Secondary pharmacological interventions have shown promise at reducing the development of posttraumatic stress disorder symptoms (PTSS) in preclinical studies. The present study examined the preliminary efficacy of a 10-day low-dose (20 mg bid) course of hydrocortisone at preventing PTSS in traumatic injury victims. METHODS:Sixty-four traumatic injury patients (34% female) were randomly assigned in a double-blind protocol to receive either a 10-day course of hydrocortisone or placebo initiated within 12 hours of the trauma. One-month and 3-months posttrauma participants completed an interview to assess PTSS and self-report measures of depression and health-related quality of life. RESULTS:Hydrocortisone recipients reported fewer PTSD and depression symptoms, and had greater improvements in health-related quality of life during the first 3 months posttrauma than did placebo recipients. Hydrocortisonerecipients who had never received prior mental health treatment had the lowest PTSD scores. CONCLUSION: Low-dose hydrocortisone may be a promising approach to the prevention of PTSD in acutely injured trauma patients, and may be particularly efficacious in acutely injured trauma victims without a history of significant psychopathology.
RCT Entities:
UNLABELLED: OBJECTIVE/ INTRODUCTION: Secondary pharmacological interventions have shown promise at reducing the development of posttraumatic stress disorder symptoms (PTSS) in preclinical studies. The present study examined the preliminary efficacy of a 10-day low-dose (20 mg bid) course of hydrocortisone at preventing PTSS in traumatic injury victims. METHODS: Sixty-four traumatic injurypatients (34% female) were randomly assigned in a double-blind protocol to receive either a 10-day course of hydrocortisone or placebo initiated within 12 hours of the trauma. One-month and 3-months posttraumaparticipants completed an interview to assess PTSS and self-report measures of depression and health-related quality of life. RESULTS:Hydrocortisone recipients reported fewer PTSD and depression symptoms, and had greater improvements in health-related quality of life during the first 3 months posttrauma than did placebo recipients. Hydrocortisone recipients who had never received prior mental health treatment had the lowest PTSD scores. CONCLUSION: Low-dose hydrocortisone may be a promising approach to the prevention of PTSD in acutely injured traumapatients, and may be particularly efficacious in acutely injured trauma victims without a history of significant psychopathology.
Authors: R J Ursano; C S Fullerton; R S Epstein; B Crowley; T C Kao; K Vance; K J Craig; A L Dougall; A Baum Journal: Am J Psychiatry Date: 1999-04 Impact factor: 18.112
Authors: E Martignoni; A Costa; E Sinforiani; A Liuzzi; P Chiodini; M Mauri; G Bono; G Nappi Journal: Psychoneuroendocrinology Date: 1992-08 Impact factor: 4.905
Authors: Duncan G Campbell; Bradford L Felker; Chuan-Fen Liu; Elizabeth M Yano; JoAnn E Kirchner; Domin Chan; Lisa V Rubenstein; Edmund F Chaney Journal: J Gen Intern Med Date: 2007-06 Impact factor: 5.128
Authors: Jessie L Frijling; Mirjam van Zuiden; Saskia B J Koch; Laura Nawijn; Dick J Veltman; Miranda Olff Journal: Soc Cogn Affect Neurosci Date: 2015-09-17 Impact factor: 3.436